[Primary Sjögren's syndrome with cutaneous vasculitis manifested as leg ulcerations] [0.03%]
以腿部溃疡为表现的原发性舍格伦综合征合并皮肤小血管炎病例报告
Sonia Cristina de Magalhães Souza,Katia Akemi Miyazato Kuruma,Danieli Castro Oliveira de Andrade et al.
Sonia Cristina de Magalhães Souza et al.
Primary Sjögren's Syndrome (pSS) is an autoimmune disease with a large spectrum of clinical manifestations extending from an organ-specific involvement to a systemic process. The skin is affected quite commonly and the estimated frequency ...
[Immunosuppression with cyclophosphamide and fudarabine, with support of autologous CD-34+ stem cells, in the treatment of severe scleroderma] [0.03%]
环磷酰胺和氟达拉滨联合自体CD３４＋干细胞救治重症系统性硬化病临床观察
Carlos Alberto von Mühlen,Everton Luís Hinterholz,Bernardo Garicochea et al.
Carlos Alberto von Mühlen et al.
Immune ablation of T lymphocytes, key players in the physiopathogenic processes leading to autoimmune diseases, may arrest scleroderma progression even in some severely ill patients. High-dose chemotherapy followed by autologous stem cell r...
Ivânio Alves Pereira
Ivânio Alves Pereira
Flávia Aiko Sakamoto,André Yui Aihara,Artur da Rocha Corrêa Fernandes et al.
Flávia Aiko Sakamoto et al.
Johanna Noordehoek,Luiz Fabio Machado Barbosa
Johanna Noordehoek
[Antibodies to beta2-glycoprotein I, autoimmunity and atherosclerosis] [0.03%]
抗β₂-糖蛋白I抗体、自身免疫与动脉粥样硬化
Aline Ranzolin,Andrei Lotterman,Jussara Bohn et al.
Aline Ranzolin et al.
Beta2-glycoprotein I (beta2-gpI) is a phospholipid cofactor with anticoagulant properties. A number of biological functions in the coagulation cascade have been attributed to this cofactor. Sera from patients with antiphospholipid syndrome ...
[Primary Sjögren's syndrome: exocrine and non-exocrine manifestations] [0.03%]
原发性舍格伦综合征的外分泌及非外分泌系统表现
Maria da Graça Henriques da Conceição Negrão Sequeira Muñoz,Walter Carlos Baptista Castelão,Fernando Manuel Diamantino Saraiva et al.
Maria da Graça Henriques da Conceição Negrão Sequeira Muñoz et al.
Objective: to characterize the exocrine and non-exocrine clinical disease manifestations of 74 patients with primary Sjögren's Syndrome (pSS). Methods: ...
[Contribution of the disease and its therapy on the SLICC/ACR-DI in early systemic lupus erythematosus] [0.03%]
[SLE疾病及其治疗对早期系统性红斑狼疮患者SLICC/ACR损伤指数的影响]
Mailze Campos Bezerra,Francisco Saraiva da Silva Júnior,Eduardo Ferreira Borba Neto et al.
Mailze Campos Bezerra et al.
The majority of the information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first five years after disease onset. However, data about early damage were rarely reported. ...
[Cumulative organ damage evaluation using SLICC/ACR-DI in patients with more than five years of systemic lupus erythematosus] [0.03%]
[SLEDAI/ACR损伤指数在系统性红斑狼疮五年生存者中的累积器官损害评估价值]
Elaine Marcelina Claudio Sella,Emilia Inoue Sato
Elaine Marcelina Claudio Sella
Objective: to evaluate the frequency of different types of irreversible lesions in systemic lupus erythematosus (SLE) patients with more than five years of disease. ...